Table 2 Adverse events.
ddAC | ddAC-CD | ddAC-CP | All conventional | High-dose | ||
|---|---|---|---|---|---|---|
Grade | n = 24 | n = 7 | n = 36 | n = 67 | n = 53 | |
Fatigue | Any | 12 (50%) | 3 (43%) | 11 (31%) | 26 (39%) | 47 (89%) |
3–4 | 2 (8%) | 1 (14%) | 0 (0%) | 3 (4%) | 21 (40%) | |
Nausea | Any | 5 (21%) | 0 (0%) | 2 (6%) | 7 (10%) | 40 (75%) |
3–4 | 1 (4%) | 0 (0%) | 0 (0%) | 1 (1%) | 13 (25%) | |
Infectiona | Any | 3 (13%) | 2 (29%) | 3 (8%) | 8 (12%) | 33 (62%) |
3–4 | 0 (0%) | 1 (14%) | 1 (3%) | 2 (3%) | 29 (55%) | |
Mucositis oral | Any | 7 (29%) | 2 (29%) | 1 (3%) | 10 (15%) | 25 (47%) |
3–4 | 2 (8%) | 1 (14%) | 0 (0%) | 3 (4%) | 10 (19%) | |
Diarrhea | Any | 1 (4%) | 2 (29%) | 0 (0%) | 3 (4%) | 23 (43%) |
3–4 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 7 (13%) | |
Vomiting | Any | 2 (8%) | 0 (0%) | 0 (0%) | 2 (3%) | 22 (42%) |
3–4 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 6 (11%) | |
Allergic reaction | Any | 0 (0%) | 1 (14%) | 0 (0%) | 1 (1%) | 19 (36%) |
3–4 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (6%) | |
Skin related adverse eventsb | Any | 2 (8%) | 6 (86%) | 1 (3%) | 9 (13%) | 10 (19%) |
3–4 | 0 (0%) | 2 (29%) | 1 (3%) | 3 (4%) | 1 (2%) | |
Pain | Any | 0 (0%) | 0 (0%) | 1 (3%) | 1 (1%) | 14 (26%) |
3–4 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (8%) | |
Gastritis, reflux or dyspepsiac | Any | 2 (8%) | 0 (0%) | 1 (3%) | 3 (4%) | 10 (19%) |
3–4 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (4%) | |
Peripheral sensory neuropathy | Any | 2 (8%) | 3 (43%) | 5 (14%) | 10 (15%) | 1 (2%) |
3–4 | 1 (4%) | 0 (0%) | 1 (3%) | 2 (3%) | 0 (0%) | |
Weight loss | Any | 3 (13%) | 0 (0%) | 0 (0%) | 3 (4%) | 6 (12%) |
3–4 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
